Search

Despite accelerating progress towards schistosomiasis control in sub-Saharan Africa, several age groups have been eclipsed by current treatment and monitoring strategies that mainly focus on school-aged children. As schistosomiasis poses a threat to people of all ages, unfortunate gaps exist in current treatment coverage and associated monitoring efforts, preventing subsequent health benefits to preschool-aged children as well as certain adolescents and adults. Expanding access to younger ages through the forthcoming pediatric praziquantel formulation and improving treatment coverage in older ages is essential. This should occur alongside formal inclusion of these groups in large-scale monitoring and evaluation activities. Current omission of these age groups from treatment and monitoring exacerbates health inequities and has long-term consequences for sustainable schistosomiasis control., (Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.)

Competing Interests: The authors have read the journal’s policy and have the following conflicts: Jutta Reinhard-Rupp was employed by Merck KGaA at the time the review article was written. She holds Merck stock options which does not impact her contribution to the article. All other authors have declared that no competing interests exist.